Clinical presentations and outcomes of children with cancer and COVID‐19: A systematic review

Meena, Jagdish Prasad; Gupta, Aditya; Tanwar, Pranay; Jat, Kana Ram; Pandey, Ravindra Mohan; Seth, Rachna

doi:10.1002/pbc.29005

Cited by 59 publications

(88 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cases of COVID-19 in children and adolescents with cancer have been reported worldwide. In the systematic review by Meena et al, 57 collecting data from 33 studies (18 case reports and 15 case series), 55, clinical and outcome of 226 children with cancer and COVID-19 were described: 53% of the patients were affected by hematological malignancies and 47% by solid tumors. The median age was seven years with a male to female ratio of 1.7:1; 34 patients were in intensive chemotherapy and 17 post-HSCT.…”

Section: Covid-19 In Children and Adolescents With Cancermentioning

confidence: 99%

Covid-19 in Children and Adolescent: Characteristics and Specificities in Immunocompetent and Oncohematological Patients

Mercolini¹,

Cesaro²

2022

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

SARS-CoV-2 pandemic affected less children and adolescents, morbidity and mortality figures being inferior to that reported for adults. In this review we focused on the clinical course, risk factors for severe COVID-19, mortality, treatment options and prevention measures in the pediatric and adolescent setting with special attention to the pediatric oncohematological patients. In this subgroups of patients, SARS-CoV-2 infection was often asyntomatic but 47 to 68% of patients require hospitalization and 9-10% of those hospitalized needed intensive care with a COVID-19 attributable mortality of about 4%. The multisystem inflammatory syndrome associated to Coronavirus 2019 was less frequent than that reported in the non-oncohematological pediatric population. Noteworthy, the course of COVID-19 was more severe in low-middle income countries. The key measures to prevent SARS-CoV-2 infection are the reduction of patients exposure to the SARS-CoV-2 and vaccination, now available fore care givers and parents and for patients and siblings > 12 years old. The treatment of COVID-19 in pediatric patients was mainly based on supportive care with dexamethasone and heparin prophylaxis for severely ill patients. Other measures, such as convalescent plasma, remdesivir and monoclonal antibodies have been used in limited case or within experimental protocols. Further studies are needed on the risk factors and outcome of SARS-CoV-2 infection in the pediatric immunocompromised patients.

show abstract

Section: Covid-19 In Children and Adolescents With Cancermentioning

confidence: 99%

Covid-19 in Children and Adolescent: Characteristics and Specificities in Immunocompetent and Oncohematological Patients

Mercolini¹,

Cesaro²

2022

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

show abstract

Section: E T T E R T O T H E E D I T O R Covid-19 Among Children With Cancer In Greece (2020): Results From the Nationwide Registry Of Chmentioning

confidence: 99%

“…Children are generally at low risk for serious complications 1 ; children with cancer (CwC), however, are vulnerable to infections mainly due to immunosuppression caused by treatment. 2 We aimed to assess the magnitude and severity of COVID-19 among CwC in Greece.An electronic survey entailing demographic characteristics, cancer type, COVID-19 infection, treatment, and outcome information among…”

mentioning

confidence: 99%

COVID‐19 among children with cancer in Greece (2020): Results from the Nationwide Registry of Childhood Hematological Malignancies and Solid Tumors (NARECHEM‐ST)

Baka

Michos

Alexopoulou

et al. 2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

“…Out of 15 deaths, four of them were not related to COVID-19. Thus, the mortality rate was 4.9% [33]. Millen et al reported 54 positive children of COVID-19 with cancer.…”

Section: Covid-19 Experience In Pediatric Oncologymentioning

confidence: 98%

Management of Covid-19 Disease in Pediatric Oncology Patients

Cakmak¹

2021

SARS-CoV-2 Origin and COVID-19 Pandemic Across the Globe

View full text Add to dashboard Cite

Pediatric cancer patients are immunocompromised, and the risks are higher in this population. Confirmed cases are defined as PCR (polymerase chain reaction) positive patients. The severity of infection is divided into four groups: asymptomatic/mild, moderate, severe, and critical, based on the clinical, laboratory, and radiological features. In the pediatric population, the COVID-19 disease has a mild course. Chemotherapy courses can be interrupted according to the symptoms and severity of the disease. Azithromycin, antivirals are used as a single agent or in combination. In critical patients, convalescent plasma, mesenchymal stem cells, tocilizumab, and granulocyte transfusions are administered. In recent studies, having hematological malignancy, stem cell transplantation, a mixed infection, and abnormal computerized tomography findings increase the severity of the disease and the need for an intensive care unit. Therefore, the patients and their families should be aware of a higher risk of severe forms than immunocompetent children.

show abstract

Clinical presentations and outcomes of children with cancer and COVID‐19: A systematic review

Cited by 59 publications

References 45 publications

Covid-19 in Children and Adolescent: Characteristics and Specificities in Immunocompetent and Oncohematological Patients

Covid-19 in Children and Adolescent: Characteristics and Specificities in Immunocompetent and Oncohematological Patients

COVID‐19 among children with cancer in Greece (2020): Results from the Nationwide Registry of Childhood Hematological Malignancies and Solid Tumors (NARECHEM‐ST)

Management of Covid-19 Disease in Pediatric Oncology Patients

Contact Info

Product

Resources

About